FKBP12–calcineurin complex (FKBP12–CaN)

The FKBP12–calcineurin complex is a ternary molecular assembly that plays a pivotal role in the intracellular signaling pathways of T-lymphocytes. It is primarily formed when the immunophilin FKBP12 (12 kDa FK506-binding protein, encoded by FKBP1A) binds to the macrocyclic lactone drug tacrolimus (FK506). This drug-protein complex then physically associates with calcineurin, a calcium-calmodulin-dependent serine/threonine protein phosphatase, effectively inhibiting its enzymatic activity (Liu et al., 1991, Cell). In a healthy immune response, calcineurin dephosphorylates the transcription factor NFAT (Nuclear Factor of Activated T-cells), enabling its translocation to the nucleus to trigger the expression of interleukin-2 and other pro-inflammatory cytokines. By blocking this dephosphorylation, the FKBP12–calcineurin complex prevents T-cell activation and proliferation, making it a primary target for immunosuppressive therapy in organ transplantation and autoimmune disorders (StatPearls, 2023). Because calcineurin is expressed in various tissues beyond the immune system, the inhibition of this complex is associated with significant side effects, including dose-dependent nephrotoxicity and metabolic disturbances.

Other names

FKBP1A–calcineurin complexFK506-binding protein 12–calcineurin complexFKBP12–PP2B complexTacrolimus–FKBP12–calcineurin complex

The complex acts via a gain-of-function mechanism where the drug (e.g., tacrolimus) binds to FKBP12, and the resulting binary complex then binds to calcineurin, sterically blocking the phosphatase's active site and preventing the dephosphorylation of NFAT (StatPearls, 2023; Liu et al., 1991).